Otsuka Weighs Family Influence In Wake Of Successful IPO
This article was originally published in PharmAsia News
Otsuka Holdings made a successful debut on the Tokyo Stock Exchange, but that also means it will be watched to see if it adheres to the policies of its founding family
You may also be interested in...
EU Approvals: Takeda advances its targeted ALK-positive NSCLC tyrosine kinase inhibitor into early lines of therapy, while Bayer and Finland’s Orion gain clearance for their androgen receptor inhibitor for prostate cancer.
The pharma giants are joining forces to help the UK reach its ambitious target of testing 100,000 people a day for coronavirus by the end of April.
Angelini is looking to take its recently-acquired ThermaCare brand to the next level by establishing a direct base in Germany to market the product and through a new distribution deal with Norway's Navamedic.